Key Takeaways
- CMS approved a 2.48% Medicare Advantage rate hike for 2027, dramatically higher than the 0.09% initially floated in January.
- Humana (HUM) shares soared 12% in after-hours trading, while UnitedHealth (UNH) and CVS Health (CVS) climbed over 6% in early Tuesday trading.
- The approved rate will deliver more than $13 billion in extra Medicare Advantage funding to health insurers in 2027.
- Other healthcare stocks rallied alongside, including Molina Healthcare (MOH) gaining 7% and Centene (CNC) adding 4%.
- Mizuho’s Jared Holz remarked the rate is “certainly better than the government’s initial rate decision,” though cautioned it’s not remarkable in isolation.
Humana (HUM) shares kicked off Tuesday trading with an impressive 11% gain following Monday evening’s revelation of the finalized 2027 Medicare Advantage reimbursement rates.
The approved 2.48% rate represents a dramatic reversal from the shockingly low 0.09% preliminary figure unveiled in January, which blindsided the healthcare industry and triggered sharp selloffs in insurer equities.
This CMS decision guarantees private health insurance companies will receive over $13 billion in extra Medicare Advantage reimbursements from federal coffers during 2027.
UnitedHealth (UNH) and CVS Health (CVS), which owns Aetna, both surged more than 6% before Tuesday’s opening bell. Elevance Health (ELV) advanced approximately 5%. Healthcare provider and managed care companies also benefited, with Molina Healthcare (MOH) jumping 7% and Centene (CNC) climbing 4%.
The rally follows intensive advocacy efforts from insurers and industry associations over recent months, who maintained the January draft failed to account for escalating medical expenditures. The Better Medicare Alliance characterized the near-zero preliminary figure as effectively a “cut,” highlighting that medical cost inflation has been tracking between 7% and 9% year-over-year.
Key Modifications in the Final Decision
Beyond the headline rate figure, CMS implemented multiple technical adjustments. Beginning in 2027, the agency will eliminate diagnosis information from unlinked chart review records when computing risk scores, while creating an exception for beneficiaries transitioning between Medicare Advantage carriers.
According to the agency, this modification will disproportionately affect plans that depend extensively on chart reviews to document patient conditions and secure elevated reimbursements. CMS additionally refreshed the Part D risk adjustment framework to incorporate Inflation Reduction Act provisions.
CMS Administrator Dr. Mehmet Oz stated the revisions are designed to maintain “coverage affordable” while ensuring enrollees receive “real value from their plans.”
Financial analysts had maintained conservative projections leading up to Monday’s disclosure. TD Cowen’s Ryan Langston had forecast a more moderate increase between 1% and 1.5%. The 2.48% result surpassed those estimates, although Mizuho’s Jared Holz offered measured commentary: “We do not believe a Medicare rate increase of 2.5% is so awesome in a vacuum, but is certainly better than the government’s initial rate decision.”
Holz observed there is now “a chance for margins to expand next year, provided the Companies continue to trim benefits and align costs with revenue.”
Why This Rate Matters So Much
Medicare Advantage currently serves approximately 35 million Americans and has experienced consistent expansion, now exceeding traditional fee-for-service Medicare enrollment. The finalized rate determines the distribution of more than half a trillion dollars annually through private insurance plans, establishing it as among the most critical metrics in the health insurance industry.
The rate calculation incorporates multiple variables including baseline cost trends, 2026 Star Ratings for performance bonuses, and risk adjustment formula modifications. CMS verified it will maintain the 2024 Medicare Advantage risk adjustment model through 2027.
Cross-party concerns about controlling Medicare Advantage expenditures had intensified uncertainty surrounding the rate-setting process. Legislators from both sides have questioned insurer documentation practices that can generate higher reimbursements for patients with more recorded medical conditions. The previous administration’s CMS had begun constraining those payments, and January’s proposal under new leadership indicated continued regulatory scrutiny.
